Document is current
Any future updates will be listed below
-
Authors
Garofolo, Monia
Vitale, Martina
Penno, Giuseppe
Solini, Anna
Orsi, Emanuela
Grancini, Valeria
Bonora, Enzo
Fondelli, Cecilia
Trevisan, Roberto
Vedovato, Monica
Nicolucci, Antonio
Pugliese, Giuseppe
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00715481 at ClinicalTrials.govDocuments that mention this clinical trial
Risk of all-cause mortality according to the European Society of Cardiology risk categories in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1007/s00592-022-01942-8
Independent association of atherogenic dyslipidaemia with all‐cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study
https://doi.org/10.1186/s12933-021-01224-7
Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1371/journal.pone.0125512
Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study
https://doi.org/10.1007/s00592-018-1133-z
Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study
https://doi.org/10.1136/bmjdrc-2020-001481
Prognostic impact of switching to the 2021 chronic kidney disease epidemiology collaboration creatinine-based equation in Caucasian patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular events (RIACE) Italian Multicenter Study
https://doi.org/10.1186/s12933-024-02450-5
Body mass index versus surrogate measures of central adiposity as independent predictors of mortality in type 2 diabetes
https://doi.org/10.1186/s12933-022-01706-2
-
Funding
Funding for this research was provided by:
Fondazione Diabete Ricerca
Diabetes, Endocrinology and Metabolism Foundation
Eli Lilly
Sigma-Tau Pharmaceuticals
Boehringer Ingelheim
Chiesi Farmaceutici
Takeda Pharmaceutical Company
- License Information
-
More Information
Article History
Received: 31 July 2024
Accepted: 19 September 2024
First Online: 24 October 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. The research protocol was approved by the ethics committee of the coordinating centre (Sant’Andrea Hospital, Rome, Italy) on 25 September 2006 (number 43/2006) and subsequently by the ethics committee of each participating centre. Participants provided an informed consent.
: Not applicable.
: MG reports receiving consultant fees from Eli Lilly, and lecture fees from Eli Lilly, Merck Sharp & Dohme, and Novo Nordisk. MVi reports receiving lecture fees from MundiPharma and Novo Nordisk. GPe reports receiving consultant fees from Bayer and Eli Lilly, and lecture fees from AstraZeneca, Boerhinger Ingelheim, Eli-Lilly, Merck Sharp & Dohme, Mundipharma, Novo Nordisk, and Takeda. AS reports receiving consultant fees from Axxam, Bayer, and Novo Nordisk, and lecture fees from Eli Lilly, Novo Nordisk, and Sanofi-Aventis. EO reports receiving consultant fees from Eli Lilly and Novo Nordisk, and lecture fees from Astellas. VG reports receiving lecture fees from Abbot, Astra-Zeneca, Medtronic, Novo Nordisk, Sanofi-Aventis, Theras, and Vertex. EB reports receiving consultant fees from Abbott, Bayer, Becton Dickinson, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, and Novo Nordisk. CF reports receiving lecture fees from Abbot, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Mundipharma, and Theras Lifetech. RT reports receiving consultant fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi-Aventis, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. MVe reports receiving lecture fees from Lifescan and Novo Nordisk. AN reports receiving grants from Artsana, Astra-Zeneca, Eli Lilly, Novo Nordisk, and Sanofi Aventis and personal fees from Eli Lilly and Novo Nordisk. GPu reports receiving consultant fees from Abbot, Bayer, and Novo Nordisk, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Mundipharma, and Novo Nordisk.
